Current Treatment Options in Neurology

, Volume 3, Issue 6, pp 479–493 | Cite as

Parkinson’s disease: Initial treatment with levodopa or dopamine agonists

  • Stewart A. Factor
Article

Opinion statement

The question of whether to use levodopa (LD) or dopamine agonists as initial therapy in Parkinson’s disease has been a controversy for nearly 20 years. There are several issues relating to this treatment regimen that may effect ones decision. Review of them results in the following conclusions:
  • •LD does not cause the onset of motor fluctuations and dyskinesia; it probably relates to disease progression.

  • •Tolerance does not develop with long-term LD therapy.

  • •LD is not toxic.

  • •LD decreases mortality in Parkinson’s disease.

  • •Motor fluctuations can occur with dopamine-agonist monotherapy, but the actual frequency is as yet unknown.

  • •Dopamine agonists are not neuroprotective.

  • Clinical trials have indicated that LD remains the most potent symptomatic therapeutic agent available.

  • •Dopamine agonists do provide some symptomatic relief when used alone in early Parkinson’s disease.

  • •Standard preparations of LD have the same effect on early disease as controlled release preparations.

  • •Dopamine agonists cause less dyskinesia and fluctuations.

These conclusions indicate that both drugs are effective symptomatic agents with their own positive and negative aspects. There is no incorrect choice. It is reasonable to start young onset patients (younger than 50 years of age) with an agonist, because they seem to be more prone to develop motor fluctuations and dyskinesia. However, if employment is in jeopardy then LD may be needed. Because agonists cause more hallucinations, freezing, and somnolence, problems of particular relevance to the elderly (older than 70 years), then LD would be the best agent for older onset patients. In general, but particularly for those falling in between these age groups, treatment should be individualized. In this time of cost effectiveness, LD remains the least expensive of these agents.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:427–442.PubMedGoogle Scholar
  2. 2.
    Cotzias GC, Papavasiliou PS, Gellene R: Modification of parkinsonism-chronic treatment with L-DOPA. N Engl J Med 1969, 280:337–345.PubMedCrossRefGoogle Scholar
  3. 3.
    Duvoisin RC: To treat early or to treat late? Ann Neurol 1987, 21:2–3.CrossRefGoogle Scholar
  4. 4.
    Melamed E: Initiation of levodopa therapy in parkinsonian patients should be delayed until advanced stages of the disease. Arch Neurol 1986, 43:402–405.PubMedGoogle Scholar
  5. 5.
    Markham CH, Diamond SG: Modification of Parkinson’s disease by long-term levodopa treatment. Arch Neurol 1986, 43:405–407.PubMedGoogle Scholar
  6. 6.
    Hachinski V: Timing of levodopa therapy. Arch Neurol 1986, 43:407.PubMedGoogle Scholar
  7. 7.
    Factor SA, Weiner WJ: Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 1993, 8:257–262.PubMedCrossRefGoogle Scholar
  8. 8.
    Weiner WJ: The initial treatment of Parkinson’s disease should begin with levodopa. Mov Disord 1999, 14:716–724.PubMedCrossRefGoogle Scholar
  9. 9.
    Montastruc JL, Rascol O, Senard J-M: Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord 1999, 14:725–730.PubMedCrossRefGoogle Scholar
  10. 10.
    Factor SA: The initial treatment of Parkinson’s disease. Mov Disord 2000, 15:360–361.PubMedCrossRefGoogle Scholar
  11. 11.
    Brooks DJ: Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000, 68:685–690.PubMedCrossRefGoogle Scholar
  12. 12.
    Shulman LM: Levodopa toxicity in Parkinson’s disease: reality or myth? Reality-practice patterns should change. Arch Neurol 2000, 57:406–407.PubMedCrossRefGoogle Scholar
  13. 13.
    Weiner WJ: Is levodopa toxic? Arch Neurol 2000, 57:408–410.PubMedCrossRefGoogle Scholar
  14. 14.
    Hachinski V: Levodopa toxicity. Arch Neurol 2000, 57:410.CrossRefGoogle Scholar
  15. 15.
    Tanner CM: Dopamine agonists in early therapy for Parkinson’s disease: Promise and problems. JAMA 2000, 284:1971–1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Barbeau A: Long-term appraisal of levodopa therapy. Neurology 1972, 22(suppl):22–24.Google Scholar
  17. 17.
    Lesser RP, Fahn S, Snider SR, et al.: Analysis of the clinical problems in parkinsonism and the complications of long term therapy. Neurology 1979, 29:1253–1260.PubMedGoogle Scholar
  18. 18.
    de Jong GJ, Meerwaldt JD, Schmitz PIM: Factors that influence the occurence of response variations in Parkinson’s disease. Ann Neurol 1987, 22:4–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Cedarbaum JM, Gandy SE, McDowell FH: "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia or dementia in Parkinson’s disease. Neurology 1991, 41:622–629.PubMedGoogle Scholar
  20. 20.
    Blin J, Bonnet A-M, Agid Y: Does Levodopa aggravate Parkinson’s disease? Neurology 1988, 38:1410–1416.PubMedGoogle Scholar
  21. 21.
    Caraceni T, Scigliano G, Musicco M: The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991, 41:380–384.PubMedGoogle Scholar
  22. 22.
    Hoehn MM: Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983, 19:253–264.Google Scholar
  23. 23.
    Horstink MW, Zijlmans JCM, Pasman JW, et al.: Severity of Parkinson’s disease is a risk factor for peak dose dyskinesia. J Neurol Neurosurg Psychiatry 1990, 53:224–226.PubMedGoogle Scholar
  24. 24.
    Roos RAC, Vredevoogd CB, van der Velde EA: Response fluctuations in Parkinson’s disease. Neurology 1990, 40:1344–1346.PubMedGoogle Scholar
  25. 25.
    Kostic VS, Marinkovic J, Svetel M, et al.: The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications. Neurology 2000, 54(suppl):A373.Google Scholar
  26. 26.
    Langston JW: The impact of MPTP on Parkinson’s disease research: past, present and future. In Parkinson’s Disease: Diagnosis and Clinical Management. Edited by Factor SA, Weiner WJ. New York: Demos; 2001:In press.Google Scholar
  27. 27.
    Fahn S: Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998, 43:551–554.PubMedCrossRefGoogle Scholar
  28. 28.
    Fabbrini G, Mouradian MM, Juncos JL, et al.: Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, part I.. Ann Neurol 1988, 24:366–371.PubMedCrossRefGoogle Scholar
  29. 29.
    Melamed E, Hefti F, Wurtman RJ: Nondopaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980, 8:558–563.PubMedCrossRefGoogle Scholar
  30. 30.
    Bravi D, Mouradian MM, Roberts JW, et al.: Wearing-off fluctuations in Parkinson’s disease: contributions of postsynaptic mechanisms. Ann Neurol 1994, 36:27–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Mouradian MM, Juncos JL, Fabbrini G, et al.: Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, part II. Ann Neurol 1988, 24:372–378.PubMedCrossRefGoogle Scholar
  32. 32.
    Mouradian MM, Heuser JE, Baronti F, Chase TN: Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 1990, 27:18–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Markham CH, Diamond SG: Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 1981, 31:125–131.PubMedGoogle Scholar
  34. 34.
    Markham CH, Diamond SG: Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol 1986, 19:365–372.PubMedCrossRefGoogle Scholar
  35. 35.
    Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992, 32:804–811.PubMedCrossRefGoogle Scholar
  36. 36.
    Olanow CW: Oxidation reactions in Parkinson’s disease. Neurology 1990, 40(suppl):32–37.PubMedGoogle Scholar
  37. 37.
    Calne DB: The free radical hypothesis in Parkinson’s disease: evidence against it. Ann Neurol 1992, 32:799–803.PubMedCrossRefGoogle Scholar
  38. 38.
    Agid Y: Levodopa: is toxicity a myth? Neurology 1998, 50:858–863.PubMedGoogle Scholar
  39. 39.
    Agid Y, Chase T, Marsden D: Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998, 351:851–852.PubMedCrossRefGoogle Scholar
  40. 40.
    Agid Y, Ahlskog E, Albanese A, et al.: Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord 1999, 14:911–913.PubMedCrossRefGoogle Scholar
  41. 41.
    Fahn S: Is Levodopa toxic? Neurology 1996, 47(suppl):S184-S195.PubMedGoogle Scholar
  42. 42.
    Olney JW, Zorumski CF, Stewart GR, et al.: Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson’s and Huntington’s diseases. Exp Neurol 1990, 108:269–272.PubMedCrossRefGoogle Scholar
  43. 43.
    Przedborski S, Jackson-Lewis V, Muthane U, et al.: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993, 34:715–723.PubMedCrossRefGoogle Scholar
  44. 44.
    Ziv I, Zilkha-Falb R, Shirvan A, et al.: Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson’s disease? Mov Disord 1997, 12:17–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Hefti F, Melamed E, Bhawan J, Wurtman RJ: Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981, 31:1194–1195.Google Scholar
  46. 46.
    Perry TL, Yong VW, Ito M, et al.: Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984, 43:990–993.PubMedCrossRefGoogle Scholar
  47. 47.
    Cotzias GC, Miller ST, Tang LC, Papavasiliou PS: Levodopa, fertility and longevity. Science 1977, 196:549–551.PubMedCrossRefGoogle Scholar
  48. 48.
    Blunt SB, Jenner P, Marsden CD: Suppressive effect of L-Dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993, 8:129–133.PubMedCrossRefGoogle Scholar
  49. 49.
    Murer MG, Dziewczapolski G, Menalled, et al.: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.. Ann Neurol 1998, 43:561–575.PubMedCrossRefGoogle Scholar
  50. 50.
    Fukuda T, Watabe K, Tanaka J: Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996, 728:274–276.PubMedGoogle Scholar
  51. 51.
    Quinn NP, Parkes D, Janota I, Marsden CD: Case report: preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa (2g) plus a decarboxylase inhibitor over a four-year period. Mov Disord 1986, 1:65–68.PubMedCrossRefGoogle Scholar
  52. 52.
    Rajput AH, Fenton ME, Birdi S, Macaulay R: Is levodopa toxic to human substantia nigra? Mov Disord 1997, 12:634–638.PubMedCrossRefGoogle Scholar
  53. 53.
    Yahr MD, Wolf A, Antunes J-L, et al.: Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972, 22(suppl):56–71.Google Scholar
  54. 54.
    Gwinn-Hardy K, Evidente VGH, Waters C, et al.: L-dopa slows the progression of familial parkinsonism. Lancet 1999, 353:1850–1851.PubMedCrossRefGoogle Scholar
  55. 55.
    Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA 2000, 284:1931–1938. This is a 2 year, double-blind comparison of levodopa and pramipexole in early PD patients. It includes an imaging arm of the study.CrossRefGoogle Scholar
  56. 56.
    Rakshi JS, Bailey DL, Uema T, et al.: Is ropinirole, a selective D2 receptor agonist, neuroprotective in early Parkinson’s disease? A [18F]dopa PET study. Neurology 1998, 50(suppl):A330.Google Scholar
  57. 57.
    Fahn S: Parkinson’s disease: the effect of levodopa and the ELLDOPA trial. Arch Neurol 1999, 56:529–535.PubMedCrossRefGoogle Scholar
  58. 58.
    Stern MB: Contemporary approaches to the pharmacotherapeutic management of Parkinson’s disease: an overview. Neurology 1997, 49(suppl):S2-S9.PubMedGoogle Scholar
  59. 59.
    Yoshikawa T, Minamiyama Y, Naito Y, et al.: Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994, 62:1034–1038.PubMedCrossRefGoogle Scholar
  60. 60.
    Carvey PM, Pieri S, Ling ZD: Attenuation of levodopainduced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997, 104:209–228.PubMedCrossRefGoogle Scholar
  61. 61.
    Felten DL, Felten SY, Fuller RW, et al.: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992, 13:339–351.PubMedCrossRefGoogle Scholar
  62. 62.
    Factor SA: Dopamine agonists. Med Clin N America 1999, 83:415–443.PubMedCrossRefGoogle Scholar
  63. 63.
    Simuni T, Hurtig H: Levodopa: 30 years of progress. In Parkinson’s Disease: Diagnosis and Clinical Management. Edited by Factor SA, Weiner WJ. New York: Demos; 2001:In press.Google Scholar
  64. 64.
    Uitti RJ, Ahlskog JE, Maraganore DM, et al.: Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology 1993, 43:1918–1926. A population-based study examining mortality in PD patients.PubMedGoogle Scholar
  65. 65.
    Diamond SG, Markham CH, Hoehn MM, et al.: Multicenter study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987, 22:8–12.PubMedCrossRefGoogle Scholar
  66. 66.
    Scigliano G, Musicco M, Soliveri P, et al.: Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease. Neurology 1990. 40:265–269.PubMedCrossRefGoogle Scholar
  67. 67.
    Przuntek H, Welzel D, Blummer E, et al.: Bromocriptine lessens the incidence of mortality in L-dopa treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992, 43:357–363.PubMedCrossRefGoogle Scholar
  68. 68.
    Yahr MD: Levodopa. Ann Int Med 1975, 83:677–682.PubMedGoogle Scholar
  69. 69.
    Sweet RD, McDowell FH: Five years’ treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann Int Med 1975, 83:456–463.PubMedGoogle Scholar
  70. 70.
    Rajput AH, Stern W, Laverly WH: Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 1984, 34:991–996.PubMedGoogle Scholar
  71. 71.
    Poewe WH, Lees AJ, Stern GM: Low dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986, 36:1528–1530.PubMedGoogle Scholar
  72. 72.
    Koller WC, Hutton JT, Tolosa E, et al.: Immediaterelease and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999, 53:1012–1019. A 5-year double blind randomized comparison of standard preparation and controlled release forms of LD.PubMedGoogle Scholar
  73. 73.
    Rinne UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 1987, 37:826–828.PubMedGoogle Scholar
  74. 74.
    Hely MA, Morris JGL, Reid WGJ, et al.: The Sidney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903–910.PubMedCrossRefGoogle Scholar
  75. 75.
    Nakanishi T, Mizuno Y, Goto I, et al.: A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson’s disease: first interim report in Japan. Eur Neurol 1988, 28(suppl):3–8.PubMedGoogle Scholar
  76. 76.
    Barone P, Bravi D, Bermejo-Pareja F, et al.: Pergolide monotherapy in the treatment of early PD: a randomized, controlled study.. Neurology 1999, 53:573–579. A 3-month, placebo-controlled, randomized, double blind trial of pergolide in early PD patients.PubMedGoogle Scholar
  77. 77.
    Adler CH, Sethi KD, Hauser RA, et al.: Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997, 49:393–399. A 6-month, placebo-controlled, randomized, double-blind, trial of ropinirole in early PD patients.PubMedGoogle Scholar
  78. 78.
    Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484–1491. This is a 5-year, double blind comparison of levodopa and ropinirole in early PD patients.PubMedCrossRefGoogle Scholar
  79. 79.
    Rascol O, Brooks DJ, Brunt ER, et al.: Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998, 13:39–45.PubMedCrossRefGoogle Scholar
  80. 80.
    Korczyn AD, Keens J, Oldham M, Macrae S: The safety and efficacy of ropinirole as early therapy in elderly patients with Parkinson’s disease. Neurology 2000, 54(suppl):A89.Google Scholar
  81. 81.
    Shannon KM, Bennett JP, Friedman JH, et al.: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997, 49:724–728. A 6-month, placebo-controlled, randomized, double blind trial of pramipexole in early PD patients.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Stewart A. Factor
    • 1
  1. 1.Parkinson’s Disease and Movement Disorders CenterAlbany Medical CenterAlbanyUSA

Personalised recommendations